To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

NCT05051865 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: camrelizumab
DRUG: SHR1020

Sponsor

Peking University Cancer Hospital & Institute